Massachusetts General Hospital (MGH) investigators have identified an inflammatory molecule that appears to play an essential role in the autoimmune disorder systemic lupus erythematosus, commonly known as lupus. In their report being published online in Nature Immunology, the researchers describe finding that a protein that regulates certain cells in the innate immune system - the body's first line of defense against infection - activates a molecular pathway known to be associated with lupus and that the protein's activity is required for the development of lupus symptoms in a mouse model of the disease.
"This study is the first demonstration that the receptor TREML4 amplifies the cellular responses transmitted through the TLR7 receptor and that a lack of such amplification prevents the inflammatory overactivation underlying lupus," says Terry Means, PhD, of the Center for Immunology and Inflammatory Diseases in the MGH Division of Rheumatology, Allergy, and Immunology. "Our preliminary results suggest that TREML4-regulated signaling through TLR7 may be a potential drug target to limit inflammation and the development of autoimmunity."
Lupus is an autoimmune disorder characterized by periodic inflammation of joints, connective tissues and organs including heart, lungs, kidneys and brain. TLR7 is one of a family of receptors present on innate immune cells like macrophages that have been linked to chronic inflammation and autoimmunity. Animal studies have suggested that overactivation of TLR7 plays a role in lupus, and a gene variant that increases expression of the receptor has been associated with increased lupus risk in human patients. The current study was designed to identify genes for other molecules required for TLR7-mediated immune cell activation.
The MGH-based team conducted an RNA-interference-based genome-scale screen of mouse macrophages, selectively knocking down the expression of around 8,000 genes, and found that TREML4 - one of a family of receptors found on granulocytes and monocytes - amplifies the response of innate immune cells to activation via TLR7. Immune cells from mice lacking TREML4 showed a weakened response to TLR7 activation. When a strain of mice genetically destined to develop a form of TLR7-dependent lupus was crossbred with a strain in which TREML4 expression was suppressed, offspring lacking TREML4 were protected from the development of lupus-associated kidney failure and had significantly lower blood levels of inflammatory factors and autoantibodies than did mice expressing TREML4.
Means notes that identifying the potential role of TREML4 in human lupus may lead to the development of drugs that could prevent or reduce the development or progression of lupus and another autoimmune disorder called Sjögren's syndrome, which also appears to involve TLR7 overactivation. Future studies are needed to better define the molecular mechanism behind TREML4-induced amplification of TLR7 signaling and to clarify beneficial reactions controlled by TREML4 - for example, the immune response to influenza virus, which the current study found was inhibited by TREML4 deficiency.
"Given that only one new drug has been approved for lupus patients in the last 50 years, there is a pressing need for more specific and less toxic drugs to treat it and other autoimmune disorders," says Means, who is an assistant professor of Medicine at Harvard Medical School.
Explore further: Biomedical engineer looks at new applications for novel lupus drug
More information: The receptor TREML4 amplifies TLR7-mediated signaling during antiviral responses and autoimmunity, DOI: 10.1038/ni.3143
Medical Xpress on facebook
Related Stories
Protein implicated in lupus promotes disease progression by distinct mechanisms in different immune cells
Patients with systemic lupus erythematosus (SLE) come under attack by their immune system, producing 'autoantibodies' that inflict damage throughout the body. Antibodies normally target foreign proteins, ...
Study points to increased risk for lupus in men
Lupus Research Institute-funded researcher Betty Tsao, PhD, at the University of California Los Angeles has discovered that humans -- males in particular -- with a variant form of the immune receptor gene "Toll Like Receptor ...
Biomedical engineer looks at new applications for novel lupus drug
Expanding on his work with a new drug that successfully treated lupus in mice, a biomedical engineer at the University of Houston has received a $250,000 grant to expand his research to a new version of the drug in an effort ...
Signaling pathway helps protect healthy tissue from overly active immune responses
Researchers have uncovered a pathway that's key for protecting healthy tissue from overly active immune responses. The findings, which are described in an upcoming issue of the Journal of the American Society of Nephrology (JASN) ...
Genetic mutation causes lupus in mice
Yale researchers have identified a genetic mutation that leads to lupus in mice. The discovery could open the way for development of therapies that target the mutation. The study appears in Cell Reports.
Recommended for you
Cigarette smoke makes superbugs more aggressive
Methicillin-resistant Staphylococcus aureus (MRSA), an antibiotic-resistant superbug, can cause life-threatening skin, bloodstream and surgical site infections or pneumonia. Researchers at the University of Cal ...
Study finds herpesvirus activates RIG-I receptor to evade body's immune system
Using herpesvirus, molecular immunologists from the University of Southern California (USC) Norris Comprehensive Cancer Center have discovered a cellular process that activates a critical immune defense against pathogens, ...
Witnessing drug problems or domestic violence causes greater asthma incidence
No home is perfect, but dysfunction in the home is now revealed to be especially dangerous for children at risk for asthma. A new study shows that children exposed to just one adverse childhood experience (ACE) had a 28 percent ...
Anticancer drug can spur immune system to fight infection
Low doses of the anti-cancer drug imatinib can spur the bone marrow to produce more innate immune cells to fight against bacterial infections, Emory researchers have found.
Investigating mutations of a crucial gene might assist treatment and prevention of asthma and other allergies
Mutations in a specific gene are linked with human susceptibility to allergic asthma according to new research. These findings suggest novel ways in which immune responses could be modulated in allergic diseases, ...
Blood test predicts severity of peanut and seafood allergies
A new blood test promises to predict which people will have severe allergic reactions to foods according to a new study led by Mount Sinai researchers and published online today in the The Annals of Allergy, Asthma & Immunology.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
Massachusetts General Hospital (MGH) investigators have identified an inflammatory molecule that appears to play an essential role in the autoimmune disorder systemic lupus erythematosus, commonly known as lupus. In their report being published online in Nature Immunology, the researchers describe finding that a protein that regulates certain cells in the innate immune system - the body's first line of defense against infection - activates a molecular pathway known to be associated with lupus and that the protein's activity is required for the development of lupus symptoms in a mouse model of the disease.
"This study is the first demonstration that the receptor TREML4 amplifies the cellular responses transmitted through the TLR7 receptor and that a lack of such amplification prevents the inflammatory overactivation underlying lupus," says Terry Means, PhD, of the Center for Immunology and Inflammatory Diseases in the MGH Division of Rheumatology, Allergy, and Immunology. "Our preliminary results suggest that TREML4-regulated signaling through TLR7 may be a potential drug target to limit inflammation and the development of autoimmunity."
Lupus is an autoimmune disorder characterized by periodic inflammation of joints, connective tissues and organs including heart, lungs, kidneys and brain. TLR7 is one of a family of receptors present on innate immune cells like macrophages that have been linked to chronic inflammation and autoimmunity. Animal studies have suggested that overactivation of TLR7 plays a role in lupus, and a gene variant that increases expression of the receptor has been associated with increased lupus risk in human patients. The current study was designed to identify genes for other molecules required for TLR7-mediated immune cell activation.
The MGH-based team conducted an RNA-interference-based genome-scale screen of mouse macrophages, selectively knocking down the expression of around 8,000 genes, and found that TREML4 - one of a family of receptors found on granulocytes and monocytes - amplifies the response of innate immune cells to activation via TLR7. Immune cells from mice lacking TREML4 showed a weakened response to TLR7 activation. When a strain of mice genetically destined to develop a form of TLR7-dependent lupus was crossbred with a strain in which TREML4 expression was suppressed, offspring lacking TREML4 were protected from the development of lupus-associated kidney failure and had significantly lower blood levels of inflammatory factors and autoantibodies than did mice expressing TREML4.
Means notes that identifying the potential role of TREML4 in human lupus may lead to the development of drugs that could prevent or reduce the development or progression of lupus and another autoimmune disorder called Sjögren's syndrome, which also appears to involve TLR7 overactivation. Future studies are needed to better define the molecular mechanism behind TREML4-induced amplification of TLR7 signaling and to clarify beneficial reactions controlled by TREML4 - for example, the immune response to influenza virus, which the current study found was inhibited by TREML4 deficiency.
"Given that only one new drug has been approved for lupus patients in the last 50 years, there is a pressing need for more specific and less toxic drugs to treat it and other autoimmune disorders," says Means, who is an assistant professor of Medicine at Harvard Medical School.
Explore further: Biomedical engineer looks at new applications for novel lupus drug
More information: The receptor TREML4 amplifies TLR7-mediated signaling during antiviral responses and autoimmunity, DOI: 10.1038/ni.3143
Medical Xpress on facebook
Related Stories
Protein implicated in lupus promotes disease progression by distinct mechanisms in different immune cells
Patients with systemic lupus erythematosus (SLE) come under attack by their immune system, producing 'autoantibodies' that inflict damage throughout the body. Antibodies normally target foreign proteins, ...
Study points to increased risk for lupus in men
Lupus Research Institute-funded researcher Betty Tsao, PhD, at the University of California Los Angeles has discovered that humans -- males in particular -- with a variant form of the immune receptor gene "Toll Like Receptor ...
Biomedical engineer looks at new applications for novel lupus drug
Expanding on his work with a new drug that successfully treated lupus in mice, a biomedical engineer at the University of Houston has received a $250,000 grant to expand his research to a new version of the drug in an effort ...
Signaling pathway helps protect healthy tissue from overly active immune responses
Researchers have uncovered a pathway that's key for protecting healthy tissue from overly active immune responses. The findings, which are described in an upcoming issue of the Journal of the American Society of Nephrology (JASN) ...
Genetic mutation causes lupus in mice
Yale researchers have identified a genetic mutation that leads to lupus in mice. The discovery could open the way for development of therapies that target the mutation. The study appears in Cell Reports.
Recommended for you
Cigarette smoke makes superbugs more aggressive
Methicillin-resistant Staphylococcus aureus (MRSA), an antibiotic-resistant superbug, can cause life-threatening skin, bloodstream and surgical site infections or pneumonia. Researchers at the University of Cal ...
Study finds herpesvirus activates RIG-I receptor to evade body's immune system
Using herpesvirus, molecular immunologists from the University of Southern California (USC) Norris Comprehensive Cancer Center have discovered a cellular process that activates a critical immune defense against pathogens, ...
Witnessing drug problems or domestic violence causes greater asthma incidence
No home is perfect, but dysfunction in the home is now revealed to be especially dangerous for children at risk for asthma. A new study shows that children exposed to just one adverse childhood experience (ACE) had a 28 percent ...
Anticancer drug can spur immune system to fight infection
Low doses of the anti-cancer drug imatinib can spur the bone marrow to produce more innate immune cells to fight against bacterial infections, Emory researchers have found.
Investigating mutations of a crucial gene might assist treatment and prevention of asthma and other allergies
Mutations in a specific gene are linked with human susceptibility to allergic asthma according to new research. These findings suggest novel ways in which immune responses could be modulated in allergic diseases, ...
Blood test predicts severity of peanut and seafood allergies
A new blood test promises to predict which people will have severe allergic reactions to foods according to a new study led by Mount Sinai researchers and published online today in the The Annals of Allergy, Asthma & Immunology.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment